No full text
Article (Scientific journals)
Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study.
Serruys, P. W.; Emanuelsson, H.; van der Giessen, W. et al.
1996In Circulation, 93 (3), p. 412-22
Peer Reviewed verified by ORBi
 

Files


Full Text
No document available.

Send to



Details



Keywords :
Aspirin/administration & dosage; Coronary Angiography; Coronary Disease/mortality/therapy; Coronary Vessels; Disease-Free Survival; Equipment Design; Exercise Test; Female; Follow-Up Studies; Heparin/administration & dosage; Humans; Length of Stay; Male; Middle Aged; Pilot Projects; Safety; Stents/adverse effects; Ticlopidine/administration & dosage; Treatment Outcome; Warfarin/administration & dosage
Abstract :
[en] BACKGROUND: The purpose of the Benestent-II Pilot Study was to evaluate the safety of delaying and eliminating anticoagulant therapy in patients receiving a heparin-coated stent in conjunction with antiplatelet drugs. METHODS AND RESULTS: The study consisted of three initial phases (I, II, III) during which resumption of heparin therapy after sheath removal was progressively deferred by 6, 12, and 36 hours. In phase IV, coumadin and heparin were replaced by 250 mg ticlopidine and 100 mg aspirin. Of the 207 patients with stable angina pectoris and a de novo lesion in whom heparin-coated stent implantation was attempted, implantation was successful in 202 patients (98%). Stent thrombosis did not occur during all four phases, and the overall clinical success rate at discharge was 99%. Bleeding complications requiring blood transfusion or surgery fell from 7.9% in phase I to 5.9%, 4%, and 0% in the three following phases. Hospital stay was 7.4, 6.1, 7.2, and 3.1 days for the consecutive phases. The restenosis rate for the combined four phases was 13% (15% in phase I, 20% in phase II, 11% in phase III, and 6% in phase IV). The overall rate of reintervention for the four phases was 8.9%. At 6 months, 84%, 75%, 94%, and 92% of the patients of phases I to IV, respectively, were event free. For the four phases, the event-free rate was 86%, which compares favorably with the rate observed in the Benestent-I study (80%; relative risk, 0.68 [0.45 to 1.04]). CONCLUSIONS: The implantation of stents coated with polyamine and end-point-attached heparin in stable patients with one significant de novo coronary lesion is well tolerated, is associated with no (sub)acute stent thrombosis, and results in a favorable event-free survival after 6 months.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Serruys, P. W.
Emanuelsson, H.
van der Giessen, W.
Lunn, A. C.
Kiemeney, F.
Macaya, C.
Rutsch, W.
Heyndrickx, G.
Suryapranata, H.
Legrand, Victor ;  Université de Liège - ULiège > Département des sciences cliniques > Cardiologie
Goy, J. J.
Materne, P.
Bonnier, H.
Morice, M. C.
Fajadet, J.
Belardi, J.
Colombo, A.
Garcia, E.
Ruygrok, P.
de Jaegere, P.
Morel, M. A.
More authors (11 more) Less
Language :
English
Title :
Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study.
Publication date :
1996
Journal title :
Circulation
ISSN :
0009-7322
eISSN :
1524-4539
Publisher :
Lippincott Williams & Wilkins, United States - Maryland
Volume :
93
Issue :
3
Pages :
412-22
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 01 June 2014

Statistics


Number of views
41 (0 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
389
Scopus citations®
without self-citations
328
OpenCitations
 
254

Bibliography


Similar publications



Contact ORBi